JP2016517857A5 - - Google Patents

Download PDF

Info

Publication number
JP2016517857A5
JP2016517857A5 JP2016509276A JP2016509276A JP2016517857A5 JP 2016517857 A5 JP2016517857 A5 JP 2016517857A5 JP 2016509276 A JP2016509276 A JP 2016509276A JP 2016509276 A JP2016509276 A JP 2016509276A JP 2016517857 A5 JP2016517857 A5 JP 2016517857A5
Authority
JP
Japan
Prior art keywords
optionally
alkyl
alkynyl
alkenyl
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016509276A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016517857A (ja
JP6388915B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2014/075257 external-priority patent/WO2014173241A1/en
Publication of JP2016517857A publication Critical patent/JP2016517857A/ja
Publication of JP2016517857A5 publication Critical patent/JP2016517857A5/ja
Application granted granted Critical
Publication of JP6388915B2 publication Critical patent/JP6388915B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016509276A 2013-04-26 2014-04-14 置換5−(3,5−ジメチルイソオキサゾール−4−イル)インドリン−2−オン Expired - Fee Related JP6388915B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2013074780 2013-04-26
CNPCT/CN2013/074780 2013-04-26
PCT/CN2014/075257 WO2014173241A1 (en) 2013-04-26 2014-04-14 Substituted5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones

Publications (3)

Publication Number Publication Date
JP2016517857A JP2016517857A (ja) 2016-06-20
JP2016517857A5 true JP2016517857A5 (OSRAM) 2017-06-01
JP6388915B2 JP6388915B2 (ja) 2018-09-12

Family

ID=51791046

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016509276A Expired - Fee Related JP6388915B2 (ja) 2013-04-26 2014-04-14 置換5−(3,5−ジメチルイソオキサゾール−4−イル)インドリン−2−オン

Country Status (12)

Country Link
US (2) US9393232B2 (OSRAM)
EP (1) EP2989096B1 (OSRAM)
JP (1) JP6388915B2 (OSRAM)
AU (1) AU2014256750B2 (OSRAM)
BR (1) BR112015027130A2 (OSRAM)
CA (1) CA2901083A1 (OSRAM)
EA (1) EA027139B1 (OSRAM)
HK (1) HK1217484A1 (OSRAM)
IL (1) IL240126A0 (OSRAM)
MX (1) MX366623B (OSRAM)
SG (1) SG11201506829XA (OSRAM)
WO (1) WO2014173241A1 (OSRAM)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
CA2895905A1 (en) 2012-12-21 2014-06-26 Zenith Epigenetics Corp. Novel heterocyclic compounds as bromodomain inhibitors
MX366703B (es) 2013-03-15 2019-07-22 Incyte Holdings Corp Heterociclos tricíclicos como inhibidores de la proteína bet.
HK1217484A1 (zh) 2013-04-26 2017-01-13 百济神州有限公司 取代的5-(3,5-二甲基异恶唑-4-基)二氢吲哚-2-酮类衍生物
WO2015004533A2 (en) 2013-06-21 2015-01-15 Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors
PL3010503T3 (pl) 2013-06-21 2020-08-24 Zenith Epigenetics Ltd. Nowe bicykliczne inhibitory bromodomen
EP3019502B1 (en) 2013-07-08 2017-05-17 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
EP3027604B1 (en) 2013-07-31 2019-02-20 Zenith Epigenetics Ltd. Novel quinazolinones as bromodomain inhibitors
WO2015081189A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
WO2015095492A1 (en) 2013-12-19 2015-06-25 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
KR102702503B1 (ko) 2014-04-23 2024-09-05 인사이트 홀딩스 코포레이션 BET 단백질의 저해제로서의 1H-피롤로[2,3-c]피리딘-7(6H)-온 및 피라졸로[3,4-c]피리딘-7(6H)-온
WO2016044130A1 (en) 2014-09-15 2016-03-24 Incyte Corporation Tricyclic heterocycles for use as bet protein inhibitors
US10710992B2 (en) 2014-12-01 2020-07-14 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
EP3227280B1 (en) 2014-12-01 2019-04-24 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
CN107207474B (zh) 2014-12-11 2021-05-07 恒翼生物医药科技(上海)有限公司 被取代的杂环作为溴结构域抑制剂
US10231953B2 (en) 2014-12-17 2019-03-19 Zenith Epigenetics Ltd. Inhibitors of bromodomains
CN111662226B (zh) 2015-01-28 2022-03-18 中国科学院广州生物医药与健康研究院 一种2-氧代-1,2-二氢苯并[cd]吲哚类化合物
GB201504694D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
WO2016203335A1 (en) 2015-06-18 2016-12-22 Pfizer Inc. Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
US20170121347A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
PH12021551886A1 (en) 2016-06-20 2023-07-17 Incyte Corp Crystalline solid forms of a bet inhibitor
CN114569606B (zh) 2016-07-29 2024-04-19 英克特诺治疗公司 吲哚啉酮化合物的用途
GB201716392D0 (en) 2017-10-06 2017-11-22 Glaxosmithkline Intellectual Property (No 2) Ltd Compounds
US11931343B2 (en) 2018-08-27 2024-03-19 Arcus Biosciences, Inc. CD73 inhibitors
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
EP4457224A4 (en) * 2021-12-29 2025-12-24 Beone Medicines I Gmbh HETEROCYCLICAL COMPOUNDS
WO2025064918A1 (en) * 2023-09-20 2025-03-27 The Board Of Regents Of The University Of Texas System First-in-class phospho-brd4 inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420970D0 (en) 2004-09-21 2004-10-20 Smithkline Beecham Corp Novel triazoloquinoline compounds
JP5478262B2 (ja) 2007-12-28 2014-04-23 田辺三菱製薬株式会社 抗癌剤
EP2303841A1 (en) * 2008-07-14 2011-04-06 Gilead Sciences, Inc. Oxindolyl inhibitor compounds
GB0919431D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919426D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
DK2722334T3 (en) 2009-11-05 2016-03-07 Glaxosmithkline Llc benzodiazepine bromdomæneinhibitor
HUE026967T2 (en) 2009-11-05 2016-07-28 Glaxosmithkline Llc Benzodiazepine Bromodomain inhibitor
WO2011069298A1 (en) 2009-12-11 2011-06-16 F. Hoffmann-La Roche Ag Novel cyclopropane indolinone derivatives
CN102656147A (zh) 2009-12-11 2012-09-05 霍夫曼-拉罗奇有限公司 可用作ampk调节剂的螺吲哚-环丙烷二氢吲哚酮
US9301962B2 (en) 2010-05-14 2016-04-05 Baylor College Of Medicine Male contraceptive compositions and methods of use
DK2571503T3 (en) 2010-05-14 2015-04-20 Dana Farber Cancer Inst Inc COMPOSITIONS AND THEIR USE IN THE TREATMENT OF NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS
ES2526671T3 (es) 2010-06-22 2015-01-14 Glaxosmithkline Llc Compuestos de benzotriazoldiazepina inhibidores de bromodominios
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
EP2699290A1 (en) 2011-04-21 2014-02-26 Sanofi-Aventis Deutschland GmbH Medicated module with lock ring
EP2705039B1 (en) 2011-05-04 2017-07-26 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
US9695179B2 (en) 2013-03-14 2017-07-04 Convergene Llc Methods and compositions for inhibition of bromodomain-containing proteins
EP2978757B1 (en) * 2013-03-27 2017-02-08 Boehringer Ingelheim International GmbH Indolinone analogues as brd4 inhibitors
HK1217484A1 (zh) 2013-04-26 2017-01-13 百济神州有限公司 取代的5-(3,5-二甲基异恶唑-4-基)二氢吲哚-2-酮类衍生物

Similar Documents

Publication Publication Date Title
JP2016517857A5 (OSRAM)
JP7402549B2 (ja) Cxcr4阻害剤およびその使用
CN112204006B (zh) 整合应激通路的调节剂
JP2013512903A5 (OSRAM)
BR112020006780A2 (pt) moduladores do estimulador de genes do interferon (sting)
TW202210465A (zh) 用於在癌症治療中對不可標定之kras進行降解標定之新穎小分子
TW201927771A (zh) 可作為蛋白質調節劑之雜環醯胺及其使用方法
US20210363136A1 (en) Modulators of the integrated stress pathway
BR112020008836A2 (pt) Moduladores da via de estresse integrada
JP2016533379A5 (OSRAM)
BR112020008825A2 (pt) moduladores da via de estresse integrada
WO2019090085A1 (en) Modulators of the integrated stress pathway
BR112020008827A2 (pt) moduladores da via de estresse integrada
TR201816176T4 (tr) Histon deasetilaz 6 inhibitörleri olarak yeni bileşikler ve bunu içeren farmasötik bileşimler.
RU2014145544A (ru) Солевая форма ингибитора гистон-метилтрансферазы ezh2 человека
JP2015532295A5 (OSRAM)
JP2016513137A5 (OSRAM)
CO2018005854A2 (es) Inhibidores de la proteína quinasa, método de preparación y uso médico de los mismos
JP2015534578A5 (OSRAM)
JP2017537164A (ja) リンパ腫の治療に使用されるヒストン脱アセチル化酵素阻害剤とベンダムスチンとの組み合わせ
EA201790088A1 (ru) Ингибиторы syk
TW201930286A (zh) 側氧哌嗪衍生物
US12304913B2 (en) Dihydropyrrolopyrazole derivative
JP2014518544A5 (OSRAM)
RU2014135436A (ru) Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака